Literature DB >> 30963593

Genetic and molecular findings of 38 Iranian patients with chronic granulomatous disease caused by p47-phox defect.

Shaghayegh Tajik1, Mohsen Badalzadeh1,2, Mohammad Reza Fazlollahi1, Massoud Houshmand3, Nasrin Bazargan4, Masoud Movahedi5, Maryam Mahlouji Rad1, Seyed Alireza Mahdaviani6, Setareh Mamishi7, Ghamar Taj Khotaei7, Davood Mansouri8, Fariborz Zandieh9, Zahra Pourpak1.   

Abstract

One of the components of NADPH oxidase is p47-phox, encoded by NCF1 gene. This study aims to find new genetic changes and clinical features in 38 Iranian patients with autosomal recessive chronic granulomatous disease (AR-CGD) caused by NCF1 gene defect. Patients who had abnormal NBT and DHR-1,2,3 assay with loss of p47-phox in Western blotting were included in this study. After recording demographic and clinical data, PCR amplification was performed followed by direct sequencing for all exons and exon-intron boundaries. The most common form of CGD in Iran was AR-CGD due to consanguinity marriages. Among patients with AR-CGD, NCF1 deficiency was found to be more common than other forms. Cutaneous involvements (53%), pulmonary infections (50%) and lymphadenopathy (29%) were more prevalent than other clinical manifestations of CGD. Mutation analysis of NCF1 gene identified five different mutations. Homozygous delta GT deletion (c.75_76delGT) was the most frequent mutation and was detected in more than 63% of families. Six families had a nonsense mutation in exon 7 (c.579G > A). Two novel mutations were found in exon 4 in two families, including a missense mutation (c.328C > T) and a nine-nucleotide deletion (c.331_339delTGTCCCCAC). Genetic detection of these mutations may result in early diagnosis and prevention of possible complications of the disease. This could be useful for timely decision-making for haematopoietic stem cell transplantation and for carrier detection as well as prenatal diagnosis of next children in the affected families. Our findings might help to predict outcomes, raise awareness and help effective treatment in these patients.
© 2019 The Foundation for the Scandinavian Journal of Immunology.

Entities:  

Keywords:  NADPH oxidase; NCF1 gene; chronic granulomatous disease; mutation; novel; p47-phox

Mesh:

Substances:

Year:  2019        PMID: 30963593     DOI: 10.1111/sji.12767

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  5 in total

1.  Late diagnosis of chronic granulomatous disease.

Authors:  T Barkai; R Somech; A Broides; R Gavrieli; B Wolach; N Marcus; D Hagin; T Stauber
Journal:  Clin Exp Immunol       Date:  2020-07-13       Impact factor: 4.330

Review 2.  A fludarabine and melphalan reduced-intensity conditioning regimen for HSCT in fifteen chronic granulomatous disease patients and a literature review.

Authors:  Mohammad Vaezi; Maryam Souri; Seyed Amin Setarehdan; Amir Ali Hamidieh; Mohammad Reza Fazlollahi; Zahra Pourpak; Mohsen Badalzadeh; Shaghayegh Tajik; Seyed Alireza Mahdaviani; Kamran Alimoghaddam; Ardeshir Ghavamzadeh
Journal:  Ann Hematol       Date:  2022-01-08       Impact factor: 3.673

3.  A Novel Mutation in the NCF2 Gene in a CGD Patient With Chronic Recurrent Pneumopathy.

Authors:  Jose Antonio Tavares de Albuquerque; Alessandra Miramontes Lima; Edgar Borges de Oliveira Junior; Edson Kiyotaka Ishizuka; Walmir Cutrim Aragão-Filho; Nuria Bengala Zurro; Sônia Mayumi Chiba; Fátima Rodrigues Fernandes; Antonio Condino-Neto
Journal:  Front Pediatr       Date:  2019-09-27       Impact factor: 3.418

4.  Lentiviral gene therapy rescues p47phox chronic granulomatous disease and the ability to fight Salmonella infection in mice.

Authors:  Andrea Schejtman; Walmir Cutrim Aragão-Filho; Simon Clare; Marta Zinicola; Maren Weisser; Siobhan O Burns; Claire Booth; Hubert B Gaspar; David C Thomas; Antonio Condino-Neto; Adrian J Thrasher; Giorgia Santilli
Journal:  Gene Ther       Date:  2020-06-12       Impact factor: 5.250

5.  Preclinical Optimization and Safety Studies of a New Lentiviral Gene Therapy for p47phox-Deficient Chronic Granulomatous Disease.

Authors:  Andrea Schejtman; Winston Vetharoy; Uimook Choi; Christine Rivat; Narda Theobald; Giuseppa Piras; Diego Leon-Rico; Karen Buckland; Elena Armenteros-Monterroso; Sara Benedetti; Michael T Ashworth; Michael Rothe; Axel Schambach; Hubert Bobby Gaspar; Elizabeth M Kang; Harry L Malech; Adrian J Thrasher; Giorgia Santilli
Journal:  Hum Gene Ther       Date:  2021-05-06       Impact factor: 5.695

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.